In the Indian Clinical Research industry, Dr. Kiran Marthak is one of pioneering leaders with a fabulous list of accomplishments and a rich experience of more than four decades.

Dr. Kiran Marthak has conducted numerous Phase 1 studies including First in Human studies, and complex clinical trials and has held senior positions in several Indian and Global pharmaceutical companies such as Ciba – Geigy (Novartis), GSK, Pfizer and Ranbaxy. He has very rich experience in conducting clinical trials across several geographies including USA, UK, Europe, China, Japan and South Africa. Dr. Marthak is highly respected amongst regulatory authorities for his knowledge of international clinical research guidelines. He is one of the accredited members for GCP training by Clinical Development Services Agency (CDSA), India and contributed to the New Clinical Trial Rules implemented in March 2019.

Dr. Marthak is a qualified M.D. in Internal Medicine from Grant Medical College, one of the oldest premier and pioneer medical institution run having 175 years of existence in the country. Additionally, Dr. Marthak is a Fellow of American College of Clinical Pharmacology, Fellow of Royal Society of Medicine, U.K. and Fellow of Faculty of Pharmacology, University of London. He has been awarded with ‘Vishist Chikitsa Medal’ in 1994, by the Association of College of Chest Physicians, India, (“ACCP”) in recognition of his services and was accepted as the honorary life member of the ACCP.

Dr. Kiran Marthak, a veteran in the Indian Clinical Research industry has more than four decades of experience in conducting clinical studies. Has held senior posts in Ciba-Geigy(now Novartis), GSK, Pfizer and Ranbaxy.

He has very rich experience in conducting clinical trials across several geographies including USA, UK, Europe, China, Japan and South Africa. Dr. Marthak is highly respected amongst regulatory authorities for his knowledge of international clinical research guidelines. He is one of the accredited members for GCP training by Clinical Development Services Agency (CDSA), India and contributed to the New Clinical Trial Rules implemented in March 2019.